A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.

This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with cetuximab in treating patients who have undergone surgery for locally advanced head and neck cancer.

Key Eligibility:

• Histologically confirmed squamous cell carcinoma (including variants, such as verrucous carcinoma, spindle cell carcinoma, or carcinoma not otherwise specified) of the head and neck, including the following subtypes: Oral cavity, Oropharynx, Larynx

• Zubrod performance status 0-1

• No prior systemic chemotherapy or anti-epidermal growth factor (EGF) therapy for this cancer
Phase III
Oral, Head and Neck
Benjamin Bridges , M.D.
RTOG (Radiation Therapy Oncology Group)
George Morris

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.